NY-IFF
IFF (NYSE: IFF) today introduced a new “Learning Labs” video series, featuring in-depth discussions with the leadership of the company’s segments and R&D function. Each video provides a comprehensive overview of IFF’s robust portfolio and enhanced capabilities following its recently completed merger with DuPont’s Nutrition and Biosciences (“N&B”) business. The complete “Learning Labs” series can be found here: ir.iff.com/events-presentations . In addition, IFF has also provided segment-level financial detail based on 2020 pro forma results.
“As a global industry leader of high-value consumer ingredients, we are pleased to provide a closer look into our capabilities, operational model and future growth potential,” said Andreas Fibig, IFF Chairman and CEO. “Stakeholder communication remains essential to IFF’s continued growth, and since combining with N&B, we have continued to explore new ways to meaningfully connect with our investors. The insights shared through our ‘Learning Labs’ series and detail provided in our 2020 pro forma segment financials is a testament to our commitment to continued transparency and greater comparability to peers.”
IFF 2020 Pro Forma Segment-Level Financial Results
To accompany the “Learning Labs” video series, IFF has provided additional detail on the financial performance, including sales and adjusted EBITDA metrics, for each of the company’s four segments on a 2020 pro forma basis.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
International Flavors & Fragrances Inc. |
|||||||||||
2020 Pro Forma Combined Reporting Segments (1)(2) |
|||||||||||
(Dollars in millions) |
|||||||||||
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Pro Forma
|
|
Pro Forma
|
|
|
|
|
|
|
|
|
|
|
|
|
Nourish Pro Forma Sales |
1,276 |
|
1,450 |
|
1,418 |
|
1,488 |
|
5,632 |
|
5,887 |
Nourish Pro Forma Adjusted Operating EBITDA |
255 |
|
303 |
|
275 |
|
257 |
|
1,090 |
|
1,153 |
as % of Pro Forma Sales |
20% |
|
21% |
|
19% |
|
17% |
|
19% |
|
20% |
|
|
|
|
|
|
|
|
|
|
|
|
Scent Pro Forma Sales |
541 |
|
475 |
|
525 |
|
524 |
|
2,064 |
|
2,064 |
Scent Pro Forma Adjusted Operating EBITDA |
118 |
|
87 |
|
118 |
|
93 |
|
416 |
|
416 |
as % of Pro Forma Sales |
22% |
|
18% |
|
22% |
|
18% |
|
20% |
|
20% |
|
|
|
|
|
|
|
|
|
|
|
|
Health & Biosciences Pro Forma Sales |
427 |
|
588 |
|
579 |
|
572 |
|
2,166 |
|
2,353 |
Health & Biosciences Pro Forma Adjusted Operating EBITDA |
131 |
|
181 |
|
172 |
|
149 |
|
634 |
|
680 |
as % of Pro Forma Sales |
31% |
|
31% |
|
30% |
|
26% |
|
29% |
|
29% |
|
|
|
|
|
|
|
|
|
|
|
|
Pharma Solutions Pro Forma Sales |
152 |
|
224 |
|
215 |
|
188 |
|
779 |
|
839 |
Pharma Solutions Pro Forma Adjusted Operating EBITDA |
42 |
|
62 |
|
61 |
|
38 |
|
203 |
|
216 |
as % of Pro Forma Sales |
28% |
|
28% |
|
28% |
|
20% |
|
26% |
|
26% |
|
|
% Change in Sales - 2020 vs. 2019 (5) |
||||||||||
|
|
Q1 (3) |
|
Q2 |
|
Q3 |
|
Q4 |
||||
|
|
Reported |
Currency
|
|
Reported |
Currency
|
|
Reported |
Currency
|
|
Reported |
Currency
|
Nourish |
|
3% |
5% |
|
(4)% |
(1)% |
|
(5)% |
(3)% |
|
—% |
1% |
Scent |
|
4% |
7% |
|
(6)% |
—% |
|
4% |
9% |
|
4% |
6% |
Health & Biosciences |
|
8% |
11% |
|
(4)% |
(2)% |
|
(1)% |
—% |
|
1% |
—% |
Pharma Solutions |
|
9% |
11% |
|
6% |
7% |
|
2% |
1% |
|
(2)% |
(4)% |
Total |
|
4% |
7% |
|
(4)% |
—% |
|
(2)% |
—% |
|
1% |
1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro Forma FY 2020
|
|
Pro Forma FY 2020 (4) |
|
|
|
|
|
|
||
|
|
Reported |
Currency
|
|
Reported |
Currency
|
|
|
|
|
|
|
Nourish |
|
(2)% |
—% |
|
(2)% |
—% |
|
|
|
|
|
|
Scent |
|
2% |
5% |
|
2% |
5% |
|
|
|
|
|
|
Health & Biosciences |
|
—% |
1% |
|
—% |
1% |
|
|
|
|
|
|
Pharma Solutions |
|
4% |
3% |
|
1% |
1% |
|
|
|
|
|
|
Total |
|
—% |
2% |
|
(1)% |
1% |
|
|
|
|
|
|
_______________________
Note: Adjusted Operating EBITDA for each segment is defined as Income (Loss) Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges, net and certain non-recurring items. Additionally, all corporate expenses have been allocated to all of the reportable segments.
- The pro forma historical segment information has been presented for informational purposes only and is not necessarily indicative of what IFF's results of operations actually would have been, had the N&B transaction occurred on the dates indicated below. In addition, the pro forma historical segment information does not purport to project the future operating results of the Company.
- Dollar amounts may not foot due to rounding.
- The first quarter and Pro Forma FY 2020 (excl. N&B Jan.) show the combination of the historical results of IFF and N&B as if the N&B transaction had been consummated on February 1, 2020. Therefore, the first quarter and Pro Forma FY 2020 (excl. N&B Jan.) do not include the N&B business for the month of January 2020, which would allow comparability against the 2021 calendar year since the merger occurred on February 1, 2021. Total N&B Sales and Adjusted Operating EBITDA included in reportable segments for the month of January 2020 amounted to $502 million and $124 million, respectively.
- Pro Forma FY 2020 shows the combination of the historical results of IFF and N&B as if the N&B Transaction had been consummated on January 1, 2020. Therefore, Pro Forma FY 2020 includes a full twelve months of 2020 N&B and IFF results.
- Effective 2021, we calculate currency neutral growth by translating current year invoiced sale amounts at the average exchange rates used for the corresponding prior year period. Previously we calculated currency neutral numbers by comparing current year results to the prior year results restated at exchange rates in effect for the current year based on the currency of the underlying transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415006035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
Deltatre Announces Acquisition of Endeavor Streaming to Create Digital and Streaming Platform Leader15.7.2025 16:15:00 CEST | Press release
Deltatre, a leading international provider of streaming, digital, data, and graphics solutions for the sports, media, and entertainment industries, today announced it has entered into a definitive agreement to acquire Endeavor Streaming from Endeavor Group Holdings, Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715833650/en/ Deltatre announces acquisition of Endeavor Streaming. In bringing together these complementary and proven digital and OTT providers, Deltatre is joining its advanced product suite – D3 VOLT, FORGE, AXIS, and DIVA, which delivers multi-functional digital experiences with integrated video – with Endeavor Streaming’s pure-play OTT product, VESPER. They will also unite their digital strategy, consulting, and direct-to-consumer growth marketing services. The combined business will be best equipped to deliver for sports, media, and entertainment clients through a compelling and comprehensive range of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom